FGFR4 Gly388Arg Polymorphism and Prostate Cancer Risk
Author Information
Author(s): Xu Bin, Tong Na, Chen Shu Q, Hua Li X, Wang Zeng J, Zhang Zheng D, Chen Ming
Primary Institution: The Affiliated ZhongDa Hospital of Southeast University
Hypothesis
The FGFR4 Gly388Arg polymorphism is associated with prostate cancer development and progression.
Conclusion
The FGFR4 Gly388Arg polymorphism is linked to an increased risk of prostate cancer development and progression.
Supporting Evidence
- The Arg388 allele increased prostate cancer risk compared with the Gly388 allele.
- Prostate cancer patients with Arg/Arg genotype had a 1.34-fold increased risk of advanced prostate cancer.
- Significantly increased prostate cancer risk was found in Asian and Caucasian populations.
Takeaway
A specific change in a gene called FGFR4 can make people more likely to get prostate cancer.
Methodology
A meta-analysis of case-control studies was conducted to assess the association between FGFR4 Gly388Arg polymorphism and prostate cancer risk using odds ratios and confidence intervals.
Potential Biases
Potential misclassification bias in control groups and lack of adjustment for confounding factors.
Limitations
Control populations were not uniform, and the study relied on unadjusted estimates without accounting for other risk factors.
Participant Demographics
The study included 2618 prostate cancer cases and 2305 controls from various ethnic backgrounds.
Statistical Information
P-Value
0.03
Confidence Interval
1.07-1.29
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website